Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lisbeth Keplinger

Podiatrist, Foot & Ankle Surgery Fullerton, CA Doctor of Podiatric Medicine

NPI 1053571828 CMS profile 319784

2141 N Harbor Blvd, Suite 35000, Fullerton, CA 92835

Open in the dashboard

General payments

$53,699

97 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisbeth Keplinger of Fullerton, CA is reported in the CMS Open Payments database as having received $53,699 across 97 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,772 16
2024 General $5,172 11
2023 General $38,987 40
2022 General $1,644 12
2019 General $4,124 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisbeth Keplinger
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Lisbeth Keplinger were reported at $3,772. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Lisbeth Keplinger Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $4,124 $389 $118–$1,406 $163
2020 $0 $191 $62–$691 $114
2021 $0 $329 $104–$1,341 $132
2022 $1,644 $419 $125–$1,611 $149
2023 $38,987 $377 $128–$1,164 $160
2024 $5,172 $394 $134–$1,168 $164
2025 $3,772 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Paragon 28, Inc. $48,332 49 payments
  2. Arthrex, Inc. $3,502 7 payments
  3. Stryker Corporation $909 24 payments
  4. Smith+Nephew, Inc. $194 4 payments
  5. Vital Orthopedics LLC $136 1 payment
  6. Nevro Corp. $135 1 payment
  7. Horizon Therapeutics plc $112 1 payment
  8. Pfizer Inc. $109 1 payment
  9. Fusion Orthopedics USA, LLC $88 2 payments
  10. Scilex Pharmaceuticals Inc. $65 1 payment
  11. Other $116 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $36,400 4 payments
  2. Travel and Lodging $9,120 27 payments
  3. Food and Beverage $5,066 64 payments
  4. Education $3,114 2 payments
Products named General payments · program years 2019–2025
  1. PORTFOLIO $44,278 31 payments
  2. Product Portfolio foot and ankle implants $865 3 payments
  3. Bun-Yo-Matic $732 3 payments
  4. PARATROOPER $647 1 payment
  5. APEX 3D $431 4 payments
  6. Additive Orthopedics $422 1 payment
  7. PRODUCT PORTFOLIO Foot And Ankle, Implants $422 1 payment
  8. PROSTEP $293 7 payments
  9. Precision MIS Bunion $273 2 payments
  10. CITREFIX $175 5 payments
  11. Other $2,019 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

110

Median for Podiatry: 160

Drug cost

$719

Median for Podiatry: $2,368

Branded share of claims

29.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 15 $229
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 32 $132
Doxycycline Hyclate Generic 23 $114
Oxycodone Hcl Generic 15 $87
Celecoxib Generic 12 $87
Cephalexin Generic 13 $70

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$72,504

Medicare's payments for the services billed

Medicare patients

314

Average age 74

Services billed

1,018

203 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 65%
Diabetes 38%
Chronic kidney disease 29%
Osteoporosis 27%
Ischemic heart disease 22%
Depression 22%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

97 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record